Pricing Log in Create free account
Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue
+39.2%
EPS
+45.6%
Free cash flow
−58.6%
Total debt
+115.1%

Quarter to September 2026, against a year earlier

105.08 17.88 −14.54%
Market cap
$14.0B
P/E
29.5×
Fwd P/E
17.9×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Halozyme Therapeutics, Inc. (HALO) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Halozyme Therapeutics, Inc. (HALO) trades at a EV/Sales of 9.0×. Over the past ten years it has ranged from 6.0× (June 2016) to 32.7× (June 2015); the current reading is higher than 43% of that period. That is in line with the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 7.7× 11.83%
FY2024 6.9× (6.63%)
FY2023 7.4× (43.85%)
FY2022 13.2× 0.74%
FY2021 13.1× (43.98%)
FY2020 23.3× 79.92%
FY2019 13.0× 5.10%
FY2018 12.3× 56.88%
FY2017 7.9× (10.61%)
FY2016 8.8× (44.43%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 8.2× 22.63%
Jun 2026 6.7× 6.31%
Mar 2026 6.3× (18.70%)
Dec 2025 7.7× 1.95%
43 more quarters

Against its own ten years

Low 6.0× High 32.7×
Ten-year median 10.9×
Current reading's percentile 47

EV/Sales against peers

Company EV/Sales
JAZZ Jazz Pharmaceuticals PLC compare 3.7×
BMRN BioMarin Pharmaceutical Inc. compare 3.9×
EXEL Exelixis, Inc. compare 6.5×
HALO Halozyme Therapeutics, Inc. 9.0×
TECH Bio-Techne Corp compare 9.3×
ASND Ascendis Pharma A/S compare 13.1×
BBIO BridgeBio Pharma, Inc. compare 15.9×
KYMR Kymera Therapeutics, Inc. compare 111×
SMMT Summit Therapeutics PLC compare 15,046×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on HALO